Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Giulia Poti"'
Autor:
Francesca Romana Di Pietro, Daniele Marinelli, Sofia Verkhovskaia, Giulia Poti, Rosa Falcone, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Zorika Christiana Di Rocco, Roberto Morese, Gabriele Piesco, Paolo Chesi, Paolo Marchetti, Cristina Maria Failla, Federica De Galitiis
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Immunotherapy with anti-PD-1 antibodies significantly improved the prognosis in advanced melanoma patients, but most of them develop primary or secondary resistance to the treatment. In this study, we evaluated efficacy and safety of a chemo
Externí odkaz:
https://doaj.org/article/d13ecc25bb244208b5becd58be273a07
Autor:
Francesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Falcone, Giulia Poti, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Roberto Morese, Zorika Christiana Di Rocco, Gabriele Piesco, Paolo Chesi, Cristina Maria Failla, Paolo Marchetti, Federica De Galitiis
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundStage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the outcome of patients with metastatic melanoma a
Externí odkaz:
https://doaj.org/article/4e3a503e397a44e9aa55f222bb49925b
Autor:
Rosa Falcone, Sofia Verkhovskaia, Francesca Romana Di Pietro, Giulia Poti, Tonia Samela, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Zorika Christiana di Rocco, Roberto Morese, Gabriele Piesco, Paolo Marchetti, Cristina Maria Failla, Federica De Galitiis
Publikováno v:
Current Oncology, Vol 31, Iss 1, Pp 588-597 (2024)
(1) Background: Mucosal melanoma (MM) is a rare tumor, accounting for about 1% of all diagnosed melanomas. The etiology and pathogenesis of this tumor are unknown. It is characterized by an aggressive phenotype with poor prognosis and a low response
Externí odkaz:
https://doaj.org/article/29b04948c1ff4e03a8a803e4687c47e1
Autor:
Vincenza Conteduca, Emanuela Scarpi, Paola Caroli, Cristian Lolli, Giorgia Gurioli, Nicole Brighi, Giulia Poti, Alberto Farolfi, Amelia Altavilla, Giuseppe Schepisi, Federica Matteucci, Giovanni Paganelli, Ugo De Giorgi
Publikováno v:
Molecular Oncology, Vol 16, Iss 2, Pp 538-548 (2022)
Plasma tumour DNA (ptDNA) is a potential early noninvasive biomarker of treatment outcome in metastatic castration‐resistant prostate cancer (mCRPC). Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC
Externí odkaz:
https://doaj.org/article/5d48a31c73474ecbbe4e84ec246466a7
Autor:
Vincenza Conteduca, Giulia Poti, Paola Caroli, Sabino Russi, Nicole Brighi, Cristian Lolli, Giuseppe Schepisi, Antonino Romeo, Federica Matteucci, Giovanni Paganelli, Paolo Marchetti, Ugo De Giorgi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Over the years, an increasing proportion of metastatic prostate cancer patients has been found to experience an initial bone flare phenomenon under both standard therapies (androgen deprivation therapy, chemotherapy, radiotherapy, abiraterone, enzalu
Externí odkaz:
https://doaj.org/article/6358497e9f7348b1ba7829da89a45252
Autor:
Vincenza Conteduca, Chiara Casadei, Emanuela Scarpi, Nicole Brighi, Giuseppe Schepisi, Cristian Lolli, Giorgia Gurioli, Ilaria Toma, Giulia Poti, Alberto Farolfi, Ugo De Giorgi
Publikováno v:
Cancers; Volume 14; Issue 9; Pages: 2219
Background: Baseline high circulating tumor DNA (ctDNA) fraction in plasma and androgen receptor (AR) copy number (CN) gain identify mCRPC patients with worse outcomes. This study aimed to assess if ctDNA associates with PSA kinetics. Methods: In thi
Autor:
Amelia Altavilla, Emanuela Scarpi, Federica Matteucci, Alberto Farolfi, Paola Caroli, Giovanni Paganelli, Cristian Lolli, Giorgia Gurioli, Ugo De Giorgi, Vincenza Conteduca, Giuseppe Schepisi, Nicole Brighi, Giulia Poti
Publikováno v:
Molecular Oncology
Università degli studi di Foggia-IRIS
Molecular Oncology, Vol 16, Iss 2, Pp 538-548 (2022)
Università degli studi di Foggia-IRIS
Molecular Oncology, Vol 16, Iss 2, Pp 538-548 (2022)
Plasma tumour DNA (ptDNA) is a potential early noninvasive biomarker of treatment outcome in metastatic castration‐resistant prostate cancer (mCRPC). Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4282b2f862a524a76a8c0c6e37e4dd5e
https://hdl.handle.net/11392/2472562
https://hdl.handle.net/11392/2472562
Autor:
Emanuela Scarpi, Giorgia Gurioli, Amelia Altavilla, Cristian Lolli, Vincenza Conteduca, A. Farolfi, Giovanni Paganelli, Federica Matteucci, Paola Caroli, Ugo De Giorgi, Giulia Poti, Nicole Brighi, Giuseppe Schepisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ef3f9a787856c2360bee1b1dd5e44cb
https://doi.org/10.1002/1878-0261.13120/v2/response1
https://doi.org/10.1002/1878-0261.13120/v2/response1
Autor:
Anna Maria Aschelter, Michela Roberto, Paolo Marchetti, Maria Bassanelli, Francesca Di Pietro, Giulia Poti, Enzo Maria Ruggeri, Silvana Giacinti, Serena Macrini, Anna Ceribelli
Publikováno v:
Anticancer Research. 38:6029-6039
Inhibiting androgen receptor (AR) signaling with androgen deprivation therapy (ADT) represents the mainstay of therapy for advanced and metastatic prostate cancer. However, about 20-60% of patients receiving first-line treatment for prostate cancer w
Autor:
Maria Laura Iaia, Giuseppe Schepisi, Giovanni Martinelli, Giorgia Ravaglia, Cristian Lolli, Giulia Poti, Amelia Altavilla, Nicole Brighi, Ugo De Giorgi, Ilaria Toma, Chiara Casadei, Vincenza Conteduca, Alberto Farolfi
Publikováno v:
Cancers, Vol 13, Iss 840, p 840 (2021)
Cancers
Università degli studi di Foggia-IRIS
Cancers
Università degli studi di Foggia-IRIS
Simple Summary Gynecological cancers represent a group of malignancies with high incidence and mortality, despite their relative sensitivity to platinum-based chemotherapy. This review aims to illustrate the state of research in the field of immunoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f72483cf0ee7d1a49877dfaaedb65e1f
http://hdl.handle.net/11585/844185
http://hdl.handle.net/11585/844185